Does inhaled salbutamol before surfactant therapy have any beneficial effect?

Beta (β)2 adrenergic receptors are present in alveolar type II cells. Previously, the beneficial effects of inhaled salbutamol treatment on respiratory outcomes were shown in premature infants with transient tachypnea of the newborn. We hypothesized that inhaled salbutamol would increase the effect...

Full description

Saved in:
Bibliographic Details
Main Authors: H Tolga Çelik, Murat Yurdakök, Ayşe Korkmaz, Şule Yiğit
Format: Article
Language:English
Published: Hacettepe University Institute of Child Health 2018-12-01
Series:The Turkish Journal of Pediatrics
Subjects:
Online Access:https://turkjpediatr.org/article/view/921
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850023967933333504
author H Tolga Çelik
Murat Yurdakök
Ayşe Korkmaz
Şule Yiğit
author_facet H Tolga Çelik
Murat Yurdakök
Ayşe Korkmaz
Şule Yiğit
author_sort H Tolga Çelik
collection DOAJ
description Beta (β)2 adrenergic receptors are present in alveolar type II cells. Previously, the beneficial effects of inhaled salbutamol treatment on respiratory outcomes were shown in premature infants with transient tachypnea of the newborn. We hypothesized that inhaled salbutamol would increase the effects of surfactant on oxygenation in premature infants with respiratory distress syndrome (RDS). Inhaled salbutamol (0.15 mg/kg) or normal saline solution (0.30 ml/ kg) was administered as a single dose by micropump nebulizer 10 minutes before the first dose of surfactant (Poractant alfa) treatment in 40 infants with gestational ages ranging from 26 to 36 weeks. The effects of salbutamol therapy were evaluated by determining the duration of respiratory support, number of doses of surfactant, respiratory rate, heart rate, fraction of inspired oxygen, and partial pressure of arterial oxygen before and after salbutamol nebulization. No statistically significant difference was detected between the two groups in duration of respiratory support, number of doses of surfactant, respiratory rate, fraction of inspired oxygen, or partial pressure of arterial oxygen. In this study, no significant effect of inhaled salbutamol treatment on the surfactant therapy in premature infants with RDS was detected.
format Article
id doaj-art-83ddc4673a184b82a809e3de2e84aa2c
institution DOAJ
issn 0041-4301
2791-6421
language English
publishDate 2018-12-01
publisher Hacettepe University Institute of Child Health
record_format Article
series The Turkish Journal of Pediatrics
spelling doaj-art-83ddc4673a184b82a809e3de2e84aa2c2025-08-20T03:01:14ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212018-12-0160610.24953/turkjped.2018.06.007Does inhaled salbutamol before surfactant therapy have any beneficial effect?H Tolga Çelik0Murat Yurdakök1Ayşe Korkmaz2Şule Yiğit3Division of Neonatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Neonatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Neonatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Neonatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey. Beta (β)2 adrenergic receptors are present in alveolar type II cells. Previously, the beneficial effects of inhaled salbutamol treatment on respiratory outcomes were shown in premature infants with transient tachypnea of the newborn. We hypothesized that inhaled salbutamol would increase the effects of surfactant on oxygenation in premature infants with respiratory distress syndrome (RDS). Inhaled salbutamol (0.15 mg/kg) or normal saline solution (0.30 ml/ kg) was administered as a single dose by micropump nebulizer 10 minutes before the first dose of surfactant (Poractant alfa) treatment in 40 infants with gestational ages ranging from 26 to 36 weeks. The effects of salbutamol therapy were evaluated by determining the duration of respiratory support, number of doses of surfactant, respiratory rate, heart rate, fraction of inspired oxygen, and partial pressure of arterial oxygen before and after salbutamol nebulization. No statistically significant difference was detected between the two groups in duration of respiratory support, number of doses of surfactant, respiratory rate, fraction of inspired oxygen, or partial pressure of arterial oxygen. In this study, no significant effect of inhaled salbutamol treatment on the surfactant therapy in premature infants with RDS was detected. https://turkjpediatr.org/article/view/921RDSinfantinhaled salbutamolneonatenewbornpremature
spellingShingle H Tolga Çelik
Murat Yurdakök
Ayşe Korkmaz
Şule Yiğit
Does inhaled salbutamol before surfactant therapy have any beneficial effect?
The Turkish Journal of Pediatrics
RDS
infant
inhaled salbutamol
neonate
newborn
premature
title Does inhaled salbutamol before surfactant therapy have any beneficial effect?
title_full Does inhaled salbutamol before surfactant therapy have any beneficial effect?
title_fullStr Does inhaled salbutamol before surfactant therapy have any beneficial effect?
title_full_unstemmed Does inhaled salbutamol before surfactant therapy have any beneficial effect?
title_short Does inhaled salbutamol before surfactant therapy have any beneficial effect?
title_sort does inhaled salbutamol before surfactant therapy have any beneficial effect
topic RDS
infant
inhaled salbutamol
neonate
newborn
premature
url https://turkjpediatr.org/article/view/921
work_keys_str_mv AT htolgacelik doesinhaledsalbutamolbeforesurfactanttherapyhaveanybeneficialeffect
AT muratyurdakok doesinhaledsalbutamolbeforesurfactanttherapyhaveanybeneficialeffect
AT aysekorkmaz doesinhaledsalbutamolbeforesurfactanttherapyhaveanybeneficialeffect
AT suleyigit doesinhaledsalbutamolbeforesurfactanttherapyhaveanybeneficialeffect